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OBJECTIVES We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized
Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the
heart rate (HR) response during the titration phase and clinical outcomes from the
three-month follow-up visit to end of study in two dosage subgroups: one that had reached
more than 100 mg of metoprolol CR/XL once daily (high-dose group; n  1,202; mean 192
mg) and one that had reached 100 mg or less (low-dose group; n  412; mean 76 mg).
BACKGROUND Clinicians have questioned whether patients need to reach the target beta-blocker dose to
receive benefit.
METHODS Outcome (Cox-adjusted) was compared with all placebo patients with dose available at the
three-month visit (n  1,845).
RESULTS Data indicated somewhat higher risk in the low-dose group compared with the high-dose
group. Heart rate was reduced to a similar degree in the two dose groups, indicating higher
sensitivity for beta-blockade in the low-dose group. The reduction in total mortality with
metoprolol CR/XL compared with placebo was similar: 38% (95% confidence interval [CI],
16 to 55) in high-dose group (p  0.0022) and also 38% (95% CI, 11 to 57) in the low-dose
group (p  0.010).
CONCLUSIONS Risk reduction was similar in the high- and low-dose subgroups, which, at least partly, may
be the result of similar beta-blockade as judged from the HR response. The results support
the idea of an individualized dose-titration regimen, which is guided by patient tolerability
and the HR response. Further research is needed to shed light on why some patients respond
with a marked HR reduction and reduced mortality risk on a relatively small dose of a
beta-blocker. (J Am Coll Cardiol 2002;40:491–8) © 2002 by the American College of
Cardiology Foundation
Randomized survival trials have reported improved survival
and reduced need for hospitalizations for worsening heart
failure (HF) with beta-adrenergic blocking agents in a broad
spectrum of patients with New York Heart Association
(NYHA) functional class II to IV HF and left ventricular
systolic dysfunction (1–4). The Cardiac Insufficiency Biso-
prolol Study (CIBIS-II), Metoprolol CR/XL Randomized
Intervention Trial in Chronic Heart Failure (MERIT-HF)
and Carvedilol Prospective Randomized Cumulative Sur-
vival study (COPERNICUS) all showed a 34% to 35%
reduction in total mortality with bisoprolol in CIBIS-II,
with metoprolol controlled-release/extended-release (CR/
XL) in MERIT-HF and with carvedilol in COPERNI-
CUS. In these trials treatment was initiated with a low
beta-blocker dose with careful titration to a predefined
maximum target dose or to the highest tolerated dose. None
of the trials was designed as a dose response study. The
beta-blocker dose could, however, be modified according to
the judgment of the investigators and according to guide-
lines as defined in the study protocols for the different trials
performed (1–5). Thus, not all patients reached the maxi-
mum target beta-blocker dose, and clinicians have ques-
tioned whether patients do, in fact, need to reach the
maximum dose to receive benefit.
In order to study outcomes in relation to the achieved
dose of one of the agents investigated, metoprolol CR/XL,
a controlled release/extended release formulation of the
beta1-selective beta-blocker metoprolol succinate, the out-
come in two subgroups from MERIT-HF were analyzed
post-hoc: one subgroup included patients who had reached
more than 100 mg of metoprolol CR/XL at the end of the
titration phase (three-month visit) and the other subgroup
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of patients who had reached 100 mg or less. This report
focuses on the heart rate (HR) response during the titration
phase, achieved plasma concentration of metoprolol succi-
nate and clinical outcomes from the three-month follow-up
visit to end of study in the two dosage subgroups.
METHODS
The MERIT-HF trial randomized a total of 3,991 patients
(2,3,5). The present analysis deals with the subgroup of
patients with dose of study medicine 0 mg at the end of
the titration phase (three-month visit; n 3,651). A total of
340 patients, 156 randomized to placebo and 184 to
metoprolol CR/XL, are not included in the present analysis;
of these, 75 had died within 90 days after the date of
randomization (40 patients randomized to placebo and 35
to metoprolol CR/XL); 116 versus 149 patients were alive at
90 days, but had dose missing; of these, 23 versus 13 died
later in the placebo and metoprolol CR/XL groups, respec-
tively.
The two primary outcome events were total mortality and
the combined end point of all-cause mortality or all-cause
hospitalization (time to first event). In addition to the two
primary end points, other predefined end points were
sudden death and death from worsening HF and also the
combined end points (time to first event) of total mortality
or hospitalization due to worsening HF and of cardiac death
or nonfatal acute myocardial infarction. Further predefined
end points were the total number of hospitalizations due to
cardiovascular causes and due to worsening HF and with-
drawal of study drug for any cause, and for worsening HF.
Inclusion and exclusion criteria for MERIT-HF have
been published earlier (2,3,5). Briefly, patients had symp-
tomatic HF in NYHA functional class II to IV and ejection
fraction0.40 and were on optimum standard therapy with
diuretics and an angiotensin-converting enzyme inhibitor.
After a single blind placebo run-in phase of two weeks,
patients were randomized to metoprolol CR/XL or placebo
with starting doses of 12.5 mg or 25 mg once daily. The
lower starting dose was recommended for patients in
NYHA functional class III/IV. It was recommended to
double the dose every second week to a maximum target
dose of 200 mg once daily or the highest tolerated dose. The
titration schedule could be modified according to the
discretion of the investigator and according to written
guidelines in the study protocol, published earlier (5).
Metoprolol plasma concentration. At the three-month
visit, a blood sample was drawn for the analysis of plasma
concentration of metoprolol succinate. Blood samples were
kept frozen at20°C until analysis, which was performed at
Bioanalytical Chemistry, AstraZeneca, Mo¨lndal, Sweden.
Metoprolol concentrations were determined by mass spec-
trometry (6). Minimum detectable concentration was about
10 nmol/l with a relative standard deviation of 10% at a
concentration of 10 nmol/l.
Statistical methods. The present analysis is post-hoc. It
should also be noted that the comparison of placebo with
the two metoprolol CR/XL dose groups does not represent
a true comparison of randomization subgroups. This is
because the placebo group and two metoprolol CR/XL dose
groups are defined according to postrandomization events:
being alive at the time of the three-month visit and with a
dose of study medicine 0 mg. In order to adjust for a
possible difference in risk between subgroups when analyz-
ing relative risk, we have applied a Cox proportional hazard
regression analysis taking into account the following base-
line risk factors: age, gender, NYHA class, ejection fraction,
history of hypertension, acute myocardial infarction and
diabetes mellitus, etiology of HF (ischemic or nonischemic)
and smoking. Furthermore, the following postrandomiza-
tion events were included in the analysis: starting dose of
study medicine (12.5 mg or 25 mg) and number of hospi-
talizations before the three-month visit. However, there are
probably other confounders present, which are unknown
and, therefore, cannot be accounted for. Thus, in the Cox
analyses of mortality and hospitalizations, we have chosen to
compare both the low-dose beta-blocker subgroup and the
high-dose beta-blocker subgroup with all placebo patients
with dose available at the three-month follow-up visit (n 
1,845). Estimates of relative risk and their 95% confidence
intervals (CI) have been obtained from the fitted models.
RESULTS
Baseline characteristics for the different subgroups are given
in Table 1. Compared with the high-dose metoprolol
CR/XL subgroup, the low-dose subgroup was slightly older
(65.9 years vs. 62.5 years) and had somewhat more patients
in NYHA functional class III/IV (67% vs. 53%). Baseline
blood pressure was somewhat lower in the low-dose sub-
group. A history of ischemic etiology of HF was slightly
more common in the low-dose group, concomitantly with a
slightly higher incidence of a history of myocardial infarc-
tion.
HR response during titration. In the low-dose metoprolol
CR/XL group, 65% of the patients started on 12.5 mg; the
corresponding figure in the high-dose group was 43%.
Mean metoprolol CR/XL dose after three months was 76
Abbreviations and Acronyms
CI  confidence interval
CIBIS II  Cardiac Insufficiency Bisoprolol
Study
COPERNICUS  Carvedilol Prospective Randomized
Cumulative Survival study
CR/XL  controlled-release/extended-release
HF  heart failure
HR  heart rate
MERIT-HF  Metoprolol CR/XL Randomized
Intervention Trial in Chronic Heart
Failure
NYHA  New York Heart Association
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mg in the low-dose group (9% on 25 mg, 30% on 50 mg,
56% on 100 mg, other 100 mg 5%) versus 192 mg in the
high-dose group (16% on 150 mg, 84% on 200 mg). The
median plasma concentration of metoprolol succinate cor-
responded well with beta-blocker dose given: 95 nmol/l
(low-dose) versus 247 nmol/l (high-dose), respectively at
the three-month follow-up visit.
Figure 1 illustrates HR in relation to achieved beta-
blocker dose during the titration phase and up to the
three-month visit. After two weeks the mean dose of
metoprolol CR/XL was 17 mg in the low-dose group, and
HR was reduced to 75 beats/min. After four weeks 32 mg,
after six weeks 64 mg and after eight weeks and three
months, the same mean metoprolol CR/XL dose was
reached, 76 mg, also with the same mean HR of 67
beats/min at the eight-week and three-month visits. After
two weeks a mean dose of 21 mg was achieved in the
high-dose group and after three months 192 mg. Thus, HR
after three months was 67 beats/min in both low-dose and
high-dose groups—a mean reduction in HR from baseline
of 13.7 versus 15.9 beats/min, respectively. This corre-
sponds to a mean HR reduction per mg metoprolol CR/XL
of 0.21 beats/min/mg in the low-dose group and 0.08
beats/min/mg in the high-dose group (p  0.0001). In the
placebo arm, HR after three months was reduced by 2.8
beats/min.
Clinical outcomes. Total mortality in the placebo group (n
 1,845) from the date of the three-month visit to end of
follow-up was 10.8% per patient year of follow-up, com-
pared with 6.8% in the two beta-blocker subgroups com-
bined (n  1,806; Table 2, Fig. 2), corresponding to a
relative risk reduction of 38% (95% CI, 20 to 53; p 
0.0003, Table 3, Fig. 3). Mortality tended to be higher in
the low-dose metoprolol CR/XL subgroup compared with
the high-dose subgroup (8.0% vs. 6.2% per patient year of
follow-up; relative risk 1.30, 95% CI, 0.87 to 1.96), but
relative risk reduction (Cox-adjusted) with metoprolol
CR/XL compared with placebo (n  1,845) was similar:
38% (95% CI, 11 to 57) in low-dose subgroup (p  0.010)
and 38% (95% CI, 16 to 55) in the high-dose subgroup
Table 1. Entry Characteristics in Relation to Dose of Study Medicine Achieved at the Three-
Month Follow-Up Visit (100 mg: Low Dose and 100 mg: High Dose)
Characteristics
Both Dose Groups Metoprolol CR/XL
Placebo
(n  1,845)
Metoprolol CR/XL
(n  1,806)
Low-Dose Group
(n  604)
High-Dose Group
(n  1,202)
Mean age (yrs) 63.6 63.7 65.9 62.5
Gender (% females) 22.8 22.4 21.5 22.8
Caucasian (%) 94 94 93 94
Ischemic etiology (%) 65 65 70 62
NYHA functional class (%) II 42 42 33 47
III 55 55 62 51
IV 3.3 3.3 5.0 2.4
Ejection fraction 0.28 0.28 0.27 0.28
SBP (mm Hg) 130 130 127 131
DBP (mm Hg) 78 79 76 80
Heart rate (beats/min) 83 83 81 83
Height (cm) 172 172 172 172
Weight (kg) 81.0 80.7 78.3 81.9
BMI (kg/m2) 27.3 27.3 26.5 27.7
S-creatinine (mol/l) 106 107 112 104
Current smoker (%) 15 14 11 16
Medical history
Previous MI (%) 49 47 54 44
Hypertension (%) 44 44 43 45
Diabetes mellitus (%) 24 25 23 26
Medications
Diuretics (%) 90 90 90 90
Furosemide (mg) 64 66 73 62
ACEI (%) 90 89 87 90
AII blocker (%) 7.0 7.0 9.1 6.0
ACEI or AII blocker (%) 97 96 96 96
Digitalis (%) 64 63 63 63
Symptoms
Peripheral pitting edema 14 15 15 15
Jugular venous distension 13 13 13 13
Pulmonary rales 11 11 11 11
Third heart sound 23 23 22 24
ACEI  angiotensin-converting enzyme inhibitor; AII  angiotensin II blocker; BMI  body mass index; CR/XL 
controlled-release/extended release; DBP  diastolic blood pressure; MI  myocardial infarction; NYHA  New York Heart
Association; SBP  systolic blood pressure.
493JACC Vol. 40, No. 3, 2002 Wikstrand et al.
August 7, 2002:491–8 Dose of Metoprolol CR/XL and Clinical Outcomes
(p  0.0022; Table 3 and Figs. 2 to 4). Test of etiology
(ischemia vs. nonischemia) by treatment interaction was
nonsignificant (p  0.19 for total mortality in the low-dose
group, unadjusted, and p  0.90 in the high-dose group).
All-cause mortality or all-cause hospitalization (time to first
event) was also reduced to a similar extent in the two dose
groups: low-dose 22% (95% CI, 7 to 34; p  0.0056) and
high-dose 29% (95% CI, 18 to 39; p  0.0001, Table 3).
Relative risk for all other prespecified end points was also
rather similar for the two beta-blocker subgroups (Tables 2
and 3, Figs. 2 to 4).
Reasons for lower than expected dose of study drug.
Table 4 presents reasons for lower than expected dose at the
three-month visit as stated by the investigators. Low HR
was the most common reason for lower than expected
beta-blocker dose at the three-month visit: stated as reason
for 10.4% of patients in the metoprolol CR/XL subgroup
compared with 2.3% in the placebo subgroup. At the
Figure 1. Illustration of the relation between achieved dose of metoprolol controlled-release/extended-release (CR/XL) and heart rate during the titration
phase and up to the three-month (mo) visit in the low-dose (open circles) and high-dose metoprolol CR/XL subgroups (solid circles). Mean dose of
metoprolol CR/XL and mean heart rate in the low-dose subgroup was the same at the eight-week (w) visit and the three-month visit. At the three-month
visit, the reduction in heart rate per milligram metoprolol CR/XL was significantly higher in the low-dose metoprolol CR/XL subgroup (0.21 beats/min
[bpm]/mg) compared with the high-dose metoprolol CR/XL subgroup (0.08 beats/min/mg, p  0.0001).
Table 2. Number of Patients With Events in Both Dose Groups Combined and in the Low-
and High-Dose Groups, Respectively
End Point
Both Dose Groups Metoprolol CR/XL
Placebo
(n  1,845)
Meto CR/XL
(n  1,806)
Low-Dose Group
(n  604)
High-Dose Group
(n  1,202)
Cause-specific mortality
Total 154 97 38 59
Cardiovascular 144 84 32 52
Sudden death 96 54 18 36
Worsening heart failure 40 21 10 11
Combined end points*
All-cause mortality or all-cause
hospitalization*
579 445 175 270
All-cause mortality or hospitalization
due to worsening heart failure*
335 185 81 104
Cardiac death or nonfatal acute MI* 162 92 36 56
Hospitalizations
All-cause 499 407 163 244
Cardiovascular cause 365 266 116 150
Worsening heart failure 224 113 57 56
*Only one event counted in each patient (the first occurring).
Meto CR/XL  metoprolol controlled-release/extended-release; MI  myocardial infarction.
494 Wikstrand et al. JACC Vol. 40, No. 3, 2002
Dose of Metoprolol CR/XL and Clinical Outcomes August 7, 2002:491–8
three-month visit, bradycardia, defined as HR below 50
beats/min, occurred in 3.6% of the patients in the beta-
blocker group and in 0.3% in the placebo group. For further
information on reasons for lower than expected dose at the
three-month visit, see reference 7.
Withdrawal of study drug. All-cause discontinuation of
placebo (n  1,845) after the three-month visit to end of
follow-up was 15.0% per patient year of follow-up (203
discontinuations); the corresponding figure in the two
beta-blocker groups combined (n  1,806) was 10.3% (141
discontinuations; risk reduction for all-cause discontinua-
tion 31%, 95% CI, 15 to 45; p  0.0006).
DISCUSSION
The results of this post-hoc subgroup analysis in relation to
dose of study medicine at the end of the titration phase
(three-month visit) in MERIT-HF showed that the major-
ity of patients tolerated the target dose of 200 mg metopro-
lol CR/XL. One-third of the patients on study medicine
Figure 2. Total mortality defined as deaths per patient years (pat. yrs) in the placebo group and in the different metoprolol controlled-release/extended-
release (CR/XL) subgroups after date of the three-month visit to end of follow-up.
Table 3. Relative Risk Reduction and 95% CI for the Comparison of the Two Dose Groups Combined (Cox Adjusted Estimates, see
Statistical Methods) and for the Comparison of the Low-Dose Metoprolol CR/XL Group With All Placebo and High-Dose
Metoprolol CR/XL Group Versus All Placebo, Respectively
End Point
All Meto CR/XL
(n  1,806)
Risk Reduction
(95% CI) %
vs. All Placebo
(n  1,845)
p Value
Low-Dose
Meto CR/XL
(n  604)
Risk Reduction
(95% CI) %
vs. All Placebo
(n  1,845)
p Value
High-Dose
Meto CR/XL
(n  1,202)
Risk Reduction
(95% CI) %
vs. All Placebo
(n  1,845)
p Value
Mortality
Total 38 (20 to 52) 0.0003 38 (11 to 57) 0.010 38 (16 to 55) 0.0022
Cardiovascular 43 (25 to 56) 0.0001 46 (20 to 63) 0.0021 41 (19 to 57) 0.0013
Sudden death 45 (23 to 60) 0.0005 50 (16 to 70) 0.0087 41 (13 to 60) 0.0072
Worsening CHF 48 (12 to 69) 0.015 53 (4 to 77) 0.038 47 (5 to 73) 0.070
Combined*
All-cause mortality/all-cause hosp. 27 (17 to 35)  0.0001 22 (7 to 34) 0.0056 29 (18 to 39)  0.0001
All-cause mortality/hosp. due to
worsening CHF
49 (39 to 58)  0.0001 42 (25 to 55)  0.0001 53 (41 to 62)  0.0001
Cardiac death/nonfatal acute MI 44 (27 to 56)  0.0001 44 (19 to 61) 0.0022 44 (24 to 59) 0.0002
Hospitalizations
All-cause 22 (12 to 32) 0.0002 15 (5 to 32) 0.14 25 (11 to 38) 0.0014
CV cause 31 (20 to 42)  0.0001 19 (2 to 37) 0.08 38 (23 to 50)  0.0001
Worsening CHF 54 (42 to 63)  0.0001 40 (17 to 57) 0.0019 62 (49 to 72)  0.0001
*Only one event counted in each patient (the first occurring).
CHF chronic heart failure; CI confidence interval; CV cardiovascular; hosp. hospitalization; Meto CR/XLmetoprolol controlled-release/extended-release; MI
myocardial infarction.
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achieved 100 mg of metoprolol CR/XL (mean, 76 mg) at
the end of the titration phase. Very interestingly, both the
low-dose and the high-dose beta-blocker subgroups reached
the same mean HR after three months of 67 beats/min, a
finding of central importance for the understanding of the
results, indicating similar effects on HR in the two meto-
prolol CR/XL subgroups in spite of the large difference in
dose given and plasma concentration of metoprolol succi-
nate achieved. The similar risk reduction, which our data
indicate, may, therefore, at least partly, be the result of
similar beta-blockade in the low- and high-dose subgroups.
Effect on clinical events. Data from the two beta-blocker
dose subgroups combined showed that, from the three-
month visit to end of follow-up, total mortality was reduced
by 38%, sudden death by 45% and hospitalizations for
worsening HF by 54%. The reduction in total mortality—
38%—is slightly higher than the 34% reported for the
complete follow-up time (2,3), and the slightly higher figure
is explained by the fact that there was very little difference in
mortality during the titration phase (the first three months
after randomization). The data showed the same reduction
in total mortality—38%—in the low-dose and high-dose
beta-blocker subgroups. Data for the other prespecified end
points also showed a similar reduction in relative risk in the
low-dose and high-dose beta-blocker subgroups.
Weak points of the present analysis. The present analysis
has two weak points: it is post-hoc and also a comparison of
nonrandomized subgroups; the groups are defined by post-
randomization events: being alive at the three-month visit
and receiving a dose of study medicine above 0 mg. The
estimates of relative risk for cause-specific mortality, for
combined end points and for number of patients hospital-
ized was performed with correction for differences in base-
line risk factors and also for some postrandomization risk
factors between the beta-blocker subgroups and the placebo
group. We cannot exclude that confounding factors not
revealed by these risk factors affected risk in the different
subgroups analyzed. However, we believe that the point
estimates along with the 95% CIs give a rough estimate of
the benefits of beta-blockade in the two different subgroups.
The data indicate that, in many patients, up-titration was
stopped due to “low HR” in patients with no symptoms of
bradycardia (7). It is not possible to know if the outcome in
the low-dose group would have been different if the patients
had been titrated to a higher dose. When interpreting this
data, one should keep in mind that MERIT-HF was not
designed as a dose-response study.
Comments on earlier performed dose-response studies.
For obvious reasons survival trials are very rarely designed as
dose-response studies. In one small six-month study (Mul-
ticenter Oral Carvedilol Heart Failure Assessment), 345
patients with mild to moderate HF were randomized to
receive treatment with placebo and three different dose
levels of carvedilol, 6.25 mg twice a day (low-dose group),
12.5 mg twice a day (medium-dose group) or 25 mg twice
a day (high-dose group) (8). The primary efficacy parameter
was submaximal exercise. Carvedilol had no detectable effect
on exercise capacity. However, carvedilol was associated
with dose-related improvements in ejection fraction. All
together, 13 deaths occurred in the placebo group and 12
deaths in the three carvedilol dose groups; 17 hospitaliza-
tions occurred in the 84 patients randomized to placebo, 9
in the 83 patients randomized to low-dose, 11 in the 89
patients randomized to medium-dose and 9 in the 89
patients randomized to high-dose carvedilol. Thus, because
of the low number of patients randomized, the study had no
power to analyze any dose-dependent effect on clinical
events in a meaningful way.
Figure 3. Relative risk and 95% confidence intervals for total mortality, sudden death and death from worsening heart failure in both beta-blocker subgroups
combined and in the low-dose and high-dose metoprolol controlled-release/extended-release (meto CR/XL) subgroups (Cox-adjusted estimates, see
Statistical Methods section). CHF  chronic heart failure.
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Sensitivity to beta1-receptor blockade. The difference in
dose between the low- and high-dose beta-blocker sub-
groups does not seem to be due to differences in body size
or body mass index, which were quite comparable in the two
dosage subgroups. Nor do the data on plasma concentration
of metoprolol succinate in the two dosage subgroups indi-
cate any difference in pharmacokinetics between the two
subgroups. Taken together, the data on the HR response
Figure 4. Cumulative percentages of all-cause mortality (top), sudden death (middle) and hospitalizations for worsening heart failure (bottom). Low-dose
metoprolol controlled-release/extended-release (CR/XL) subgroup is illustrated in the left hand panel and high-dose metoprolol CR/XL group in the right
hand panel (Cox-adjusted estimates. Estimates of risk have been obtained from the fitted models explaining why the graphs for the placebo groups have
a different appearance in the low- and high-dose subgroups; see Statistical Methods section).
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during the titration phase and plasma concentration of
metoprolol succinate at the three-month visit suggest that
the patients in the low-dose group were more sensitive to
beta-blockade than the patients in the high-dose group and
that physicians titrated the beta-blocker, at least partly,
based on the HR response. One might speculate that the
increased sensitivity to beta1-receptor blockade in the low-
dose group is caused by a downregulation and desensitiza-
tion of myocardial beta1-receptors due to more advanced
HF of the patients in the low-dose subgroup compared with
the high-dose subgroup (9–11).
Reasons for lower than expected dose. An analysis of the
reasons for lower than expected dose at the three-month
visit revealed that “low HR” was the most common reason
stated in the beta-blocker group. However, the prevalence
of bradycardia defined as HR 50 beats/min was low. This
indicates that physicians titrated, at least partly, to avoid
bradycardia. Those at risk for bradycardia in clinical practice
are mainly patients with sick sinus node and atrioventricular
block. Such patients were probably excluded by the proto-
col, which listed patients with HRs below 68 beats/min at
enrollment, and patients with atrioventricular block as
specific exclusion criteria.
Tolerability. Discontinuation of study medicine occurred
less often on metoprolol CR/XL than on placebo after the
three-month visit. For patients still on study medicine at the
end of the titration phase, metoprolol CR/XL is very well
tolerated during long-term maintenance HF therapy.
Conclusions. In summary, the low-dose group included
high-risk patients, and HR was reduced more per each
milligram of metoprolol CR/XL in the low-dose group
compared with the high-dose group, 0.21 versus 0.08
beats/min/mg, a highly significant difference. The HR
response indicates a similar degree of beta-blockade in the
two beta-blocker subgroups despite the large difference in
beta-blocker dose given and plasma concentration of meto-
prolol CR/XL achieved. The similar risk reduction, which
our data indicate, may, therefore, at least partly, be the result
of similar beta-blockade in the low- and high-dose sub-
groups. Prognosis clearly seems to be improved for the
group of higher risk patients where the investigators made
the judgment not to increase the dose to the maximum
target dose of 200 mg metoprolol CR/XL. The maximum
target dose of 200 mg metoprolol CR/XL, reached by most
patients with heart failure in MERIT-HF, should, however,
not be reduced but strived for in all patients who tolerate
this dose. The results support the idea of an individualized
dose-titration regimen, which is guided by patient tolera-
bility and the HR response. Further research is needed to
shed light on why some patients respond with a marked HR
reduction and reduced mortality risk on a relatively small
dose of a beta-blocker.
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